Comparison of healthy controls with each IBD treatment group (anti-TNF, vedolizumab, ustekinumab and azathioprine) showed no significant differences in anti-S-IgG levels and binding inhibition by sVNT. Here, TNF is linked to inflammatory bowel disease.